Hagens Berman Sobol Shapiro LLP is spearheading the investigation into Embecta (NASDAQ: EMBC) following claims that management misrepresented the company’s commercial health between November 25, 2025, and May 4, 2026. While leadership repeatedly described the pen needle portfolio as resilient, the lawsuit contends the company faced mounting competitive losses and retail market weakness that were ignored in official financial guidance.
The discrepancy surfaced on May 5, 2026, when Embecta reported a sharp revenue decline. The fallout was immediate: the company reduced its full-year adjusted EPS guidance by 43% and slashed its quarterly dividend from $0.15 to $0.01 per share. Shares plummeted 57.8% in one day as the market recalibrated to the new disclosures. Reed Kathrein, the partner leading the firm's legal team, is now examining whether management recklessly disregarded internal data while maintaining a positive outlook for investors.
Comments (0)
No comments yet. Be the first!